Tesamorelin + Ipamorelin Blend: Stack Considerations

For a wholesale buyer, the central consideration with a tesamorelin and ipamorelin blend is analytical, not commercial. A pre-mixed vial is substantially harder to verify than two single-compound vials, because one HPLC trace has to resolve two peptides with different chemistries and then attribute purity and related substances to each of them separately. Real Peptides stocks tesamorelin and ipamorelin as individual research-use-only compounds, each with its own batch testing and a publicly verifiable certificate of analysis. These are not FDA-approved drugs, they are not for human consumption, and Real Peptides does not publish combination, use, or preparation guidance in any form.

That distinction — separate SKUs with separate documentation versus a single blended vial with one summary document — is the decision most of this article is about. Everything downstream of it, from what your purchasing spec should say to what your counsel needs to review, follows from how verifiable the material in the vial actually is.

Why a pre-mixed vial is harder to document than two vials

High-performance liquid chromatography reports purity as a per-analyte figure. On a single-compound lyophilized vial, a 99%-plus HPLC result means the target peptide produces a dominant peak and the remaining area is quantified as related substances — truncated sequences, deletion products, residual synthesis artifacts. That is a clean, auditable statement about one molecule.

Put two peptides in the same vial and the chromatogram changes character. It now contains two target peaks plus the combined impurity profile of both inputs. Where those profiles overlap in retention time, a related substance from one peptide can sit under the peak of the other or co-elute with it. The result is not necessarily wrong, but it is far less transparent, and it requires a method developed and validated specifically for that mixture rather than a standard single-analyte method.

A blend also introduces a question a single-compound vial never raises: is the stated ratio of the two peptides accurate? Purity and ratio are different measurements. Purity tells you how much of what is present is the intended molecule. Ratio requires a quantitative assay against reference standards for both peptides. A document that reports only purity has not answered the ratio question at all, and plenty of blend paperwork in this market never addresses it.

Then there is traceability. A blend is manufactured from two source lots, which means the finished vial has a parent chain behind it. Ask which lot numbers went into it. Ask whether the inputs were tested before blending, after, or both. If the finished blend returns an out-of-specification result, a single summary document gives you no way to determine which input was responsible — which makes a supplier-side investigation, a credit, or a recall decision much messier than it needs to be.

None of this makes blends inherently illegitimate. It makes them harder to verify, and verification is the entire basis on which a wholesale buyer should be choosing a supplier.

What these two compounds are in the research literature

Tesamorelin is a synthetic analog of growth hormone-releasing hormone. Structurally it is a 44-amino-acid peptide carrying a trans-3-hexenoyl group at the N-terminus, a modification research describes as improving resistance to enzymatic degradation relative to unmodified GHRH. In model systems, studies describe it as acting at GHRH receptors on the anterior pituitary.

Ipamorelin is a much smaller molecule — a pentapeptide — and it works through a different receptor entirely. Research characterizes it as an agonist at the growth hormone secretagogue receptor, the same receptor targeted by ghrelin, and the literature frequently notes its selectivity relative to earlier secretagogue compounds.

The reason these two appear together in research-market discussion is that they probe two distinct signaling pathways rather than one. That is a mechanistic rationale found in the literature, not a claim of combined effect, and it should not be carried into any customer-facing copy as one. Published work on both molecules sits largely in preclinical and controlled clinical contexts that have nothing to do with the research-chemical supply market, and none of it constitutes guidance for how a reseller should describe, pair, or position a product.

Buyers evaluating this category often look at other GHRH-analog chemistry alongside tesamorelin, which is why catalogs in this space tend to carry several related compounds. Treat each as its own sourcing decision with its own documentation, not as a bundle.

The questions to put to any supplier before you stock either compound

The following is the short list worth sending to a prospective supplier in writing. The value is less in the answers than in how readily they are produced — a vendor who has this material organized will send it the same day.

One pattern worth naming: some sellers in this market treat the certificate of analysis as a premium add-on rather than a standard inclusion, and others publish testing claims that cannot be checked against any document at all. Both practices shift verification cost and risk onto you. A COA you cannot independently open and read is functionally the same as no COA.

Handling and storage belong in your purchasing specification

Peptides arrive as lyophilized powder for a reason — the dry state is considerably more stable than solution. Your purchasing spec should therefore address the conditions the material travels and sits under, because that is the part of product quality you actually control after it leaves the supplier.

Ask how vials are packed for transit, whether temperature-controlled packaging is used, and how the supplier handles warm-weather shipping. Ask what storage conditions the supplier specifies for received inventory and whether those conditions differ for short-term holding versus longer storage. Record those conditions in your own inventory procedure so that your internal handling matches what the supplier's stability information assumes.

This is also where blends create a quiet downstream problem. Two peptides do not degrade on the same timeline, and in a mixture the shorter-stability component effectively governs the useful life of the whole vial. With separate SKUs, each compound carries its own stability profile and its own inventory rotation, and you are not discarding a usable quantity of one because the other has drifted.

On preparation: Real Peptides does not provide reconstitution, dilution, titration, or administration guidance for any item, because these are research-use-only materials and that guidance is the responsibility of qualified personnel working under their own validated protocols. The only framework that belongs in a purchasing conversation is the labeled specification itself — the milligram content stated per vial. How that figure is used is a question for the end user's protocol, not for a supplier's marketing copy, and a vendor offering step-by-step preparation instructions alongside a research compound is telling you something about how seriously they take the research-use boundary.

Regulatory questions that belong with your counsel, not your supplier

This section is informational and is not legal advice. The honest position is that the questions below do not have universal answers, and anyone who gives you one without reviewing your specific business structure is overreaching.

The questions worth putting to a qualified attorney and, where applicable, to your state licensing board include: how research-use-only materials are treated for a business with your license type and structure; what labeling and record-keeping obligations attach to holding or reselling them; whether your professional licensure imposes restrictions beyond general commercial rules; what your supplier agreements say about resale, relabeling, and private labeling; and what your insurer expects to see documented. Requirements differ meaningfully between jurisdictions and they change, so a current answer matters more than a general one.

What a supplier can reasonably be expected to provide is documentation — accurate COAs, clear research-use-only labeling, traceable lot numbers, and straightforward answers about origin and testing. What a supplier cannot provide is a determination about your compliance posture. Keep those two things separate in your evaluation.

What Real Peptides does differently

Real Peptides tests every batch to a 99%-plus HPLC purity specification and runs a seven-panel batch testing protocol rather than a single purity check. Certificates of analysis are publicly verifiable — a prospective partner can open the lab results and read them before applying, rather than requesting them from a sales representative or paying for them as an extra. Orders are fulfilled from within the United States on a stated five-to-seven-day window, which is a figure buyers can plan inventory against instead of guessing at international transit.

Tesamorelin and ipamorelin are stocked as separate research-use-only compounds, each with its own lot-matched documentation, for exactly the analytical reasons described above. And the Wholesale Partner Program runs on a three-step application rather than a drawn-out sales process: apply, get reviewed for approval, and begin ordering at partner pricing.

Where this leaves a qualified buyer

If you are a med spa, clinic, telehealth operator, or reseller building a catalog in this category, the practical next move is to run the supplier questions above against whoever you are currently buying from, then apply to the Real Peptides Wholesale Partner Program and compare the documentation side by side before committing inventory to either compound.

Research into GHRH-analog chemistry is one part of a broader catalog, and buyers evaluating this category commonly look at Tesamorelin 10mg and Ipamorelin 10mg alongside related secretagogue chemistry such as CJC-1295 No DAC 10mg, with the wider Growth Factor & Tissue Signaling Research collection and the Popular Peptides range showing how the same purity specification and batch testing standard applies across every SKU.